Dongkook Pharmaceutical Co Ltd - ESG Rating & Company Profile powered by AI
The page is a zero-cost Environmental, Social and Governance analysis for Dongkook Pharmaceutical Co Ltd. The SDG score for Dongkook Pharmaceutical Co Ltd represents the company's transparency towards the United Nations SDGs. This Disclosure score covers 17 United Nations Sustainable Development Goals including: 'Zero Hunger', 'Reduced Inequalities' and 'Peace, Justice & Strong Institutions'.
Dongkook Pharmaceutical Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Dongkook Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Dongkook Pharmaceutical Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Dongkook Pharmaceutical Co Ltd disclose current and historical energy intensity?
Does Dongkook Pharmaceutical Co Ltd report the average age of the workforce?
Does Dongkook Pharmaceutical Co Ltd reference operational or capital allocation in relation to climate change?
Does Dongkook Pharmaceutical Co Ltd disclose its ethnicity pay gap?
Does Dongkook Pharmaceutical Co Ltd disclose cybersecurity risks?
Does Dongkook Pharmaceutical Co Ltd offer flexible work?
Does Dongkook Pharmaceutical Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Dongkook Pharmaceutical Co Ltd disclose the number of employees in R&D functions?
Does Dongkook Pharmaceutical Co Ltd conduct supply chain audits?
Does Dongkook Pharmaceutical Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Dongkook Pharmaceutical Co Ltd conduct 360 degree staff reviews?
Does Dongkook Pharmaceutical Co Ltd disclose the individual responsible for D&I?
Does Dongkook Pharmaceutical Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Dongkook Pharmaceutical Co Ltd disclose current and / or historical scope 2 emissions?
Does Dongkook Pharmaceutical Co Ltd disclose water use targets?
Does Dongkook Pharmaceutical Co Ltd have careers partnerships with academic institutions?
Did Dongkook Pharmaceutical Co Ltd have a product recall in the last two years?
Does Dongkook Pharmaceutical Co Ltd disclose incidents of discrimination?
Does Dongkook Pharmaceutical Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Dongkook Pharmaceutical Co Ltd issued a profit warning in the past 24 months?
Does Dongkook Pharmaceutical Co Ltd disclose parental leave metrics?
Does Dongkook Pharmaceutical Co Ltd disclose climate scenario or pathway analysis?
Does Dongkook Pharmaceutical Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Dongkook Pharmaceutical Co Ltd disclose the pay ratio of women to men?
Does Dongkook Pharmaceutical Co Ltd support suppliers with sustainability related research and development?
Does Dongkook Pharmaceutical Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Dongkook Pharmaceutical Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Dongkook Pharmaceutical Co Ltd involved in embryonic stem cell research?
Does Dongkook Pharmaceutical Co Ltd disclose GHG and Air Emissions intensity?
Does Dongkook Pharmaceutical Co Ltd disclose its waste policy?
Does Dongkook Pharmaceutical Co Ltd report according to TCFD requirements?
Does Dongkook Pharmaceutical Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Dongkook Pharmaceutical Co Ltd disclose energy use targets?
Does Dongkook Pharmaceutical Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Dongkook Pharmaceutical Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Dongkook Pharmaceutical Co Ltd
These potential risks are based on the size, segment and geographies of the company.
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. It produces active pharmaceutical ingredients, including propofol, streptokinase, and teicoplanin; disposable syringes; and pills, capsules, and ointments, as well as small volume parentral, large volume parentral, and lyophilized injectable drug injections. The company also offers Teicon, Durakinase, and Lorelin Depot injections; produces various natural product materials, such as black cohosh extract and magnolia extract comprises ETIZM and TECA; and natural herb medicines. In addition, it provides general and prescription-based drugs; medical devices; ETC and cosmetic products; and quasi drugs that include lipossol hydrocare bandage. DongKook Pharmaceutical Co., Ltd. also exports its products to approximately 40 countries, including Japan, Europe, Central and South America, and India. The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.